Efficacy of daclatasvir plus asunaprevir in elderly patients (>75 years of age) with chronic HCV genotype 1 infection

DOI Web Site Web Site 2 Citations 5 References

Bibliographic Information

Other Title
  • 高齢（＞75歳）のC型慢性肝疾患患者に於けるDAA 2剤（DCV＋ASV）治療の有効性
  • コウレイ(>75サイ)ノ Cガタ マンセイ カン シッカン カンジャ ニ オケル DAA2ザイ(DCV+ASV)チリョウ ノ ユウコウセイ

Search this article

Abstract

<p>To investigate the efficacy of daclatasvir plus asunaprevir (DCV/ASV) in elderly patients (>75 years of age), 30 patients with chronic HCV genotype 1 infection, who had no resistant mutations in the HCV NS3/NS5A regions at baseline, including 11 patients aged 76-87 years, were treated with DCV/ASV for 24 weeks. Sustained virologic response 24 weeks after treatment (SVR24) was achieved by 28 (93%) of the 30 patients, with comparable SVR24 rates between the age groups of ≤75 years (95%, 18/19) and >75 years (91%, 10/11), and by 6 (86%) of 7 patients with compensated cirrhosis. These results suggest that DCV/ASV can achieve a high rate of SVR even in elderly patients (>75 years of age) without pre-existing NS3/NS5A resistant mutations.</p>

Journal

  • Kanzo

    Kanzo 57 (9), 499-501, 2016

    The Japan Society of Hepatology

Citations (2)*help

See more

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top